This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Oxytocin for frontotemporal dementia: A randomized dose-finding study of safety and tolerability


Finger, E. C., MacKinley, J., Blair, M., Oliver, L. D., Jesso, S., Tartaglia, M. C., Borrie, M., Wells, J., Dziobek, I., Pasternak, S., Mitchell, D. G. V., Rankin, K., Kertesz, A., Boxer, A.


Neurology, Volume: 84, No.: 2, Pages.: 174-181

Year of Publication



Objective: To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal dementia (FTD). Methods: We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible doses of intranasal oxytocin (24, 48, or 72 IU) administered twice daily for 1 week to 23 patients with behavioral variant FTD or semantic dementia ( registration number NCT01386333). Primary outcome measures were safety and tolerability at each dose. Secondary measures explored efficacy across the combined oxytocin vs placebo groups and examined potential dose-related effects. Results: All 3 doses of intranasal oxytocin were safe and well tolerated. Conclusions: A multicenter trial is warranted to determine the therapeutic efficacy of long-term intranasal oxytocin for behavioral symptoms in FTD. Classification of evidence: This study provides Class I evidence that for patients with FTD, intranasal oxytocin is not significantly associated with adverse events or significant changes in the overall neuropsychiatric inventory. (PsycINFO Database Record (c) 2015 APA, all rights reserved). (journal abstract)

Bibtex Citation

@article{Finger_2014, doi = {10.1212/wnl.0000000000001133}, url = {}, year = 2014, month = {dec}, publisher = {Ovid Technologies (Wolters Kluwer Health)}, volume = {84}, number = {2}, pages = {174--181}, author = {E. C. Finger and J. MacKinley and M. Blair and L. D. Oliver and S. Jesso and M. C. Tartaglia and M. Borrie and J. Wells and I. Dziobek and S. Pasternak and D. G. V. Mitchell and K. Rankin and A. Kertesz and A. Boxer}, title = {Oxytocin for frontotemporal dementia: A randomized dose-finding study of safety and tolerability}, journal = {Neurology} }


clinical trial, clinical trials, drug therapy, drug tolerance, frontotemporal dementia, intranasal, oxytocin, safety, semantic dementia, tolerability

Countries of Study


Types of Dementia

Fronto Temporal (also known as Pick’s Disease)

Types of Study

Randomised Controlled Trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions